TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19905912

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg + Loratadine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone 200 mu g/twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast + Loratadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 0
Study: 17023730

Group type: EXPERIMENTAL
Intervention: Secondhand smoke (SHS) exposure
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GSTM1-null genotype
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GSTP1 Ile105 genotype
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Responses to SHS and DEPs
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GSTM1-null and GSTP1 Ile/Ile genotypes
Number of subjects: 19

Group type: COMPARATOR
Intervention: Clean air exposure
Number of subjects: 19
Study: 15492298

Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg once daily)
Number of subjects: 4576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4576
Study: 11119172

Group type: EXPERIMENTAL
Intervention: Biweekly automated telephone assessments with telephone follow‐up by diabetes nurse educators
Number of subjects: 570

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 570

Group type: COMPARATOR
Intervention: County clinic patients
Number of subjects: 570

Group type: COMPARATOR
Intervention: VA patients
Number of subjects: 570
Study: 7636321

Group type: EXPERIMENTAL
Intervention: Combined hyperthermia and radiotherapy (30.0 Gy in 2 weeks or 34.5 Gy in 3 weeks with heat treatments)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Schedule A: 30.0 Gy with heat twice weekly (4 treatments)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Schedule B: 34.5 Gy with heat once weekly (3 treatments)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Schedule C: 34.5 Gy with heat twice weekly (6 treatments)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combined hyperthermia and radiotherapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combined hyperthermia and radiotherapy (915 MHz)
Number of subjects: 69
Study: 2571627

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 19
Study: 68844

Group type: EXPERIMENTAL
Intervention: Bleomycin and radiation
Number of subjects: 136

Group type: COMPARATOR
Intervention: Radiation only (Control)
Number of subjects: 136
Study: 30617139

Group type: EXPERIMENTAL
Intervention: ABP 215
Number of subjects: 642

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 642
Study: 28388454

Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (C‐CT)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 172
Study: 25418606

Group type: EXPERIMENTAL
Intervention: Short implants (6 mm)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Long implants (11-15 mm) with sinus grafting
Number of subjects: 101
Study: 25476084

Group type: EXPERIMENTAL
Intervention: Transcutaneous tracheostomy tube
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional silica gel tube
Number of subjects: 32
Study: 22113345

Group type: EXPERIMENTAL
Intervention: 300 μg aleglitazar
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3000 μg aleglitazar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin
Number of subjects: 0
Study: 20645218

Group type: EXPERIMENTAL
Intervention: Helping Alliance Questionnaire-I (HAQ-I)
Number of subjects: 142
Study: 17620371

Group type: EXPERIMENTAL
Intervention: Continuous infusion of imipenem-cilastatin (loading dose of 1 g/1 g, followed by 2 g/2 g per 24 h for 3 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intermittent short-term infusion of imipenem-cilastatin (1 g/1 g three times per day for 3 days, total daily dose 3 g/3 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (Continuous and Intermittent infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous infusion
Number of subjects: 20
Study: 15896431

Group type: EXPERIMENTAL
Intervention: Total daily energy intake of REE x 1.7
Number of subjects: 0

Group type: COMPARATOR
Intervention: Total daily energy intake of REE x 1.3
Number of subjects: 0
Study: 12410192

Group type: EXPERIMENTAL
Intervention: Pamidronate (intravenous), administered daily for 3 consecutive days, repeated at 3-month intervals for one year
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (plain saline, intravenous), administered daily for 3 consecutive days, repeated at 3-month intervals for one year
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pamidronate (intravenous)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (plain saline, intravenous)
Number of subjects: 12
Study: 9704328

Group type: EXPERIMENTAL
Intervention: Instructional ski video
Number of subjects: 763
Study: 8916057

Group type: EXPERIMENTAL
Intervention: Constant target frequency of 0.8 Hz for following square step targets with an eccentricity of +/- 20 degrees.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition of the manoeuvre using the target frequency of 0.8 Hz.
Number of subjects: 0
Study: 1924666

Group type: EXPERIMENTAL
Intervention: Fluphenazine hydrochloride at 5 mg, 10 mg, or 20 mg daily for 4 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluphenazine hydrochloride
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluphenazine N‐oxide
Number of subjects: 72
Study: 6805618

Group type: EXPERIMENTAL
Intervention: Wound isolator
Number of subjects: 291

Group type: COMPARATOR
Intervention: Standard gamma‐irradiated adhesive dressing
Number of subjects: 291
Study: 30194553

Group type: EXPERIMENTAL
Intervention: ESWT with PBMT
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ESWT (once a week)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PBMT (three times a week)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham-PBMT (three times a week)
Number of subjects: 120
Study: 27810267

Group type: EXPERIMENTAL
Intervention: High‐intensity functional exercise program
Number of subjects: 186

Group type: COMPARATOR
Intervention: Seated attention control activity
Number of subjects: 186
Study: 25754414

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix (mix 50 before breakfast and lunch plus mix 25 before dinner)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Basal-bolus therapy (insulin glargine at bedtime plus prandial insulin lispro thrice-daily)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix
Number of subjects: 402

Group type: COMPARATOR
Intervention: Basal-bolus therapy
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 402
Study: 23581911

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 1699
Study: 22014840

Group type: EXPERIMENTAL
Intervention: Mild ischemic mitral regurgitation (IMR)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no IMR)
Number of subjects: 35
Study: 19888840

Group type: EXPERIMENTAL
Intervention: Foot gymnastics group (FG)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Training group (TG)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 56
Study: 16713523

Group type: EXPERIMENTAL
Intervention: Informed Consent Questionnaire (ICQ)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: ICQ-4 (four-item subscale of the ICQ)
Number of subjects: 1092
Study: 14691621

Group type: EXPERIMENTAL
Intervention: 100 mg tramadol (intraarticular)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 50 mg tramadol (intraarticular)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 20 mg tramadol (intraarticular)
Number of subjects: 210

Group type: COMPARATOR
Intervention: 0.9% NaCl (intraarticular)
Number of subjects: 210

Group type: COMPARATOR
Intervention: 100 mg tramadol (intravenous)
Number of subjects: 210

Group type: COMPARATOR
Intervention: 50 mg tramadol (intravenous)
Number of subjects: 210

Group type: COMPARATOR
Intervention: 20 mg tramadol (intravenous)
Number of subjects: 210
Study: 11771912

Group type: EXPERIMENTAL
Intervention: Nurse home visitation program over 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 0
Study: 1308699

Group type: EXPERIMENTAL
Intervention: Rich-monounsaturated fat diet (RMF) with avocado
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Free monounsaturated-enriched diet (FME) with avocado
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-saturated fat diet (LSF) without avocado
Number of subjects: 16
Study: 6741804

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (STK)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous streptokinase (STK)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Successful recanalization (either route)
Number of subjects: 28
Study: 31780038

Group type: EXPERIMENTAL
Intervention: Synbiotics (500 mg capsule containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum plus inulin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29493868

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27172587

Group type: EXPERIMENTAL
Intervention: Group A - three questions about alcohol consumption
Number of subjects: 3594

Group type: COMPARATOR
Intervention: Group B - seven questions about alcohol dependence followed by three alcohol consumption questions
Number of subjects: 3594
Study: 24854414

Group type: EXPERIMENTAL
Intervention: Scrambled kit lists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double randomized kit lists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked kit lists
Number of subjects: 0
Study: 22531205

Group type: EXPERIMENTAL
Intervention: Sodium valproate administration (minimum 750 mg/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Discontinuation of sodium valproate administration
Number of subjects: 42
Study: 19963274

Group type: EXPERIMENTAL
Intervention: Quetiapine (average daily dose=232mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study: 18622465

Group type: EXPERIMENTAL
Intervention: Chili group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 50
Study: 15569820

Group type: EXPERIMENTAL
Intervention: Exercise training (bicycle ergometer at approximately 60% of maximal oxygen consumption for 30 minutes per day, 5 days per week for 8 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Deconditioning (after 8 weeks of training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (sedentary subjects without training)
Number of subjects: 30
Study: 12941063

Group type: EXPERIMENTAL
Intervention: Climodien (estradiol valerate 2 mg + dienogest 3 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Estradiol valerate 2 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: All three compounds (Climodien, Estradiol valerate, Placebo)
Number of subjects: 51
Study: 10653047

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8787364

Group type: EXPERIMENTAL
Intervention: Acellular diphtheria/pertussis/tetanus (ADPT) vaccines
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Whole-cell diphtheria-pertussis-tetanus (WCDPT) vaccine
Number of subjects: 1182
Study: 1832906

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate and 5‐fluorouracil (CMF)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin and 5‐fluorouracil (CAF)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Mitolactol (dibromodulcitol), doxorubicin and vincristine alternating after every three cycles with three cycles of CMF (DAV/CMF)
Number of subjects: 172
Study: 4067975

Group type: EXPERIMENTAL
Intervention: Haemarthrosis aspiration
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-aspiration
Number of subjects: 14
Study: 29384705

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing intervention based on motivational interviewing (MI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 28
Study: 26782313

Group type: EXPERIMENTAL
Intervention: Vigorous intensity treadmill walking exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Seated quiet rest
Number of subjects: 14
Study: 24555753

Group type: EXPERIMENTAL
Intervention: High-dose clarithromycin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Low-dose clarithromycin
Number of subjects: 43
Study: 23876282

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Attention placebo (rhythm pedagogic program)
Number of subjects: 78
Study: 21654616

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ultrasound Therapy (US)
Number of subjects: 30
Study: 18474151

Group type: EXPERIMENTAL
Intervention: Jessner's solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30% salicylic acid
Number of subjects: 60
Study: 17136873

Group type: EXPERIMENTAL
Intervention: Cetirizine plus pseudoephedrine (C+P)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Loratadine plus pseudoephedrine (L+P)
Number of subjects: 51
Study: 14578243

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 756

Group type: COMPARATOR
Intervention: Human NPH insulin
Number of subjects: 756
Study: 11054327

Group type: EXPERIMENTAL
Intervention: Ketorolac (group K)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Prednisolone (group P)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination therapy (group C)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of group C with group P
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of group C with group K
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall improvement in visual acuity
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Time to improvement
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Contrast sensitivity and fluorescein angiography
Number of subjects: 28
Study: 8627066

Group type: EXPERIMENTAL
Intervention: Proinflammatory cytokines (TNF-alpha, IL-6, IL-8) and counterinflammatory compounds (IL-10, sTNFR-55, sTNFR-75) levels
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Interval between appearance of petechiae and blood sampling
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Plasminogen activator inhibitor (PAI)-1 levels
Number of subjects: 38
Study: 1471279

Group type: EXPERIMENTAL
Intervention: EMG-biofeedback and cheek taping, 2-3 times a week, each session of 15 minutes
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Total group (both intervention and control)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patients with right-sided facial palsy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Questionnaire about emotional reactions
Number of subjects: 35
Study: 6588975

Group type: EXPERIMENTAL
Intervention: Clofibate 1 g b.i.d.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nicotinic acid 3 g/day (b.i.d. or t.i.d.)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Nicotinic acid 3.0 g/day (alternate to previous schedule) and gemfibrozil 1.2 g/d in divided doses
Number of subjects: 5
Study: 31711464

Group type: EXPERIMENTAL
Intervention: Measles Vaccination (MV)
Number of subjects: 28000

Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccination (OPV)
Number of subjects: 28000

Group type: COMPARATOR
Intervention: Health check-up
Number of subjects: 28000
Study: 30462765

Group type: EXPERIMENTAL
Intervention: Family religiosity (measured by frequency of religious practice)
Number of subjects: 1134
Study: 26463708

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 303

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 303
Study: 24708204

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) abatacept (125 mg weekly) with IV loading (∼10 mg/kg on Day 1)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Intravenous (IV) abatacept (∼10 mg/kg monthly)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) abatacept
Number of subjects: 118

Group type: COMPARATOR
Intervention: Intravenous (IV) abatacept
Number of subjects: 118
Study: 22198427

Group type: EXPERIMENTAL
Intervention: Thin bronchoscopic method
Number of subjects: 203

Group type: COMPARATOR
Intervention: Guide sheath method
Number of subjects: 203
Study: 20426797

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 10 mg kg(‐1) day(‐1) for 30 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (gallbladders removed for neoplastic diseases)
Number of subjects: 0
Study: 17285422

Group type: EXPERIMENTAL
Intervention: Wire-guided cannula (WGC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-wire-guided cannula (non-WGC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Wire-guided cannula (WGC) among less experienced operators
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-wire-guided cannula (non-WGC) among less experienced operators
Number of subjects: 100
Study: 15591329

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 180
Study: 11871383

Group type: EXPERIMENTAL
Intervention: Plain-formulated aspirin (PF)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Extended-release aspirin (EX2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Extended-release aspirin (EX5)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Extended-release formulations (EX2 and EX5)
Number of subjects: 6
Study: 10470743

Group type: EXPERIMENTAL
Intervention: EPA+GLA
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 146
Study: 8561282

Group type: EXPERIMENTAL
Intervention: Alcoholic drinks to attain a breath alcohol level of 0.10
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2350476

Group type: EXPERIMENTAL
Intervention: Vita-Stat automatic blood pressure recorder
Number of subjects: 518

Group type: COMPARATOR
Intervention: Random-Zero sphygmomanometer
Number of subjects: 518
Study: 94176

Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (SCT) 3 x 20 micrograms = 300 MRCU intravenously for 6 days
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 31975479

Group type: EXPERIMENTAL
Intervention: Flexible visitation policy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (restricted visitation)
Number of subjects: 60
Study: 30659553

Group type: EXPERIMENTAL
Intervention: Fluorescence examination using OralID
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional oral examination under white light
Number of subjects: 98
Study: 28112412

Group type: EXPERIMENTAL
Intervention: Outreach support including an online forum, email, and telephone support
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual Cognitive Stimulation Therapy control group
Number of subjects: 241
Study: 25497262

Group type: EXPERIMENTAL
Intervention: Daily consumption of eggs (breakfast with 2 eggs)
Number of subjects: 32
Study: 22893555

Group type: EXPERIMENTAL
Intervention: Vinyl bags
Number of subjects: 41

Group type: COMPARATOR
Intervention: Thermal mattress
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vinyl bags (subgroup: birth weight <750 g)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Thermal mattress (subgroup: birth weight <750 g)
Number of subjects: 41
Study: 21059665

Group type: EXPERIMENTAL
Intervention: Ice therapy (repeated application of crushed ice)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control treatment (not specified)
Number of subjects: 19
Study: 19075297

Group type: EXPERIMENTAL
Intervention: Cognitively congruent video programming
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control video (local news program)
Number of subjects: 24
Study: 16542202

Group type: EXPERIMENTAL
Intervention: SLV317 (250 mg oral solution)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: SLV317
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15991587

Group type: EXPERIMENTAL
Intervention: Level II (Intensive Outpatient Treatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Level III (Medically Monitored Residential Treatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Observational data
Number of subjects: 12
Study: 11104556

Group type: EXPERIMENTAL
Intervention: Single agent carboplatin (400 mg/m², administered on day 1 of a 21-day cycle for a total of 4 cycles)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Etoposide + cisplatin (EP)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Single agent carboplatin
Number of subjects: 130
Study: 9095076

Group type: EXPERIMENTAL
Intervention: Low sodium diet (n = 231)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Low sodium diet (n = 71)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Control group (n = 245)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Control group (n = 96)
Number of subjects: 476
Study: 7693881

Group type: EXPERIMENTAL
Intervention: Clinical staging plus subtotal nodal irradiation (STNI)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Staging laparotomy plus treatment adaptation (adjuvant chemotherapy only in the 33% with negative laparotomy)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 578

Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 578

Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 578